{"name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","slug":"suzhou-zelgen-biopharmaceuticals-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"ZG2001 Tosilate Tablets","genericName":"ZG2001 Tosilate Tablets","slug":"zg2001-tosilate-tablets","indication":"Other","status":"phase_1"},{"name":"Alkotinib","genericName":"Alkotinib","slug":"alkotinib","indication":"Other","status":"phase_1"},{"name":"Jaktinib","genericName":"Jaktinib","slug":"jaktinib","indication":"Other","status":"phase_3"},{"name":"Placebo to match Hydroxycarbamide","genericName":"Placebo to match Hydroxycarbamide","slug":"placebo-to-match-hydroxycarbamide","indication":"Control arm in Phase 3 clinical trials (indication depends on the active hydroxycarbamide trial)","status":"phase_3"},{"name":"Placebo to match Jaktinib","genericName":"Placebo to match Jaktinib","slug":"placebo-to-match-jaktinib","indication":"Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial)","status":"phase_3"},{"name":"ZG19018","genericName":"ZG19018","slug":"zg19018","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Hydroxycarbamide Tablets","genericName":"Hydroxycarbamide Tablets","slug":"hydroxycarbamide-tablets","indication":"Sickle cell disease","status":"phase_3"},{"name":"ZG006","genericName":"ZG006","slug":"zg006","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Rifampicin Capsules","genericName":"Rifampicin Capsules","slug":"rifampicin-capsules","indication":"Tuberculosis (pulmonary and extrapulmonary)","status":"marketed"}]}],"pipeline":[{"name":"ZG2001 Tosilate Tablets","genericName":"ZG2001 Tosilate Tablets","slug":"zg2001-tosilate-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Alkotinib","genericName":"Alkotinib","slug":"alkotinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Hydroxycarbamide Tablets","genericName":"Hydroxycarbamide Tablets","slug":"hydroxycarbamide-tablets","phase":"phase_3","mechanism":"Hydroxycarbamide inhibits ribonucleotide reductase, reducing deoxynucleotide synthesis and promoting fetal hemoglobin production while decreasing sickling and hemolysis.","indications":["Sickle cell disease","Chronic myeloid leukemia","Polycythemia vera","Essential thrombocythemia"],"catalyst":""},{"name":"Jaktinib","genericName":"Jaktinib","slug":"jaktinib","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo to match Hydroxycarbamide","genericName":"Placebo to match Hydroxycarbamide","slug":"placebo-to-match-hydroxycarbamide","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration of hydroxycarbamide for use as a control in clinical trials.","indications":["Control arm in Phase 3 clinical trials (indication depends on the active hydroxycarbamide trial)"],"catalyst":""},{"name":"Placebo to match Jaktinib","genericName":"Placebo to match Jaktinib","slug":"placebo-to-match-jaktinib","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration of Jaktinib, a JAK inhibitor, for use as a control in clinical trials.","indications":["Control arm in Phase 3 clinical trials of Jaktinib (indication determined by parent drug trial)"],"catalyst":""},{"name":"Rifampicin Capsules","genericName":"Rifampicin Capsules","slug":"rifampicin-capsules","phase":"marketed","mechanism":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","indications":["Tuberculosis (pulmonary and extrapulmonary)","Leprosy","Atypical mycobacterial infections","Prophylaxis of meningococcal meningitis","Brucellosis"],"catalyst":""},{"name":"ZG006","genericName":"ZG006","slug":"zg006","phase":"phase_3","mechanism":"ZG006 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"ZG19018","genericName":"ZG19018","slug":"zg19018","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-30","type":"pipeline","source":"simplywall.st","summary":"Asian Market Opportunities: 3 Stocks That May Be Priced Below Their Estimated Value - simplywall.st","headline":"Asian Market Opportunities: 3 Stocks That May Be Priced Below Their Estimated Value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNUjZoQlVWNVVvQ3VWOUhQTVVTVU1qeFI0QUpzTUdWM0RjV1lQb254Y3NBdTJGUjBiZjlWZDlnTkpuallfblBGZXMyNzJTV3dfY19veDFlY21LMkhOa2pncDRGd0pnV0N4eWItc29RQk1NbFBjSG1iZTcyN0ItUk85cUVITEpBdjUxeXIxU0ZhT296aDY3c0RNSnNVb1pTX1ppdHBPRFZLRi0yVnVOUXVnNVh0ajYzUVhDeEtqWFJSeVhkaGwyZ3VUNVZRODlESTVKcmlVTll6SFU0NjZDcG54Qk9rXzlhUy1ud29Fb19zZHE0MUE?oc=5","date":"2026-03-27","type":"pipeline","source":"Barchart.com","summary":"PD-1 and PD-L1 Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlook - Barchart.com","headline":"PD-1 and PD-L1 Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, Leading Companies, and Future Outlo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMUtNeXAxZWhJV1Y1S3N3cWR3OC1CS0YxSF9yNXZ6TThtOUdzN1dlUS1CaHhfaWQxRE1CUVVaWXFGVW4yR1lxdGtGRkNpZVptdGhuNTVrUHFDRFZ5cTNIT2w1c0RvM1c2Qm5mbnMyYWdCNHhEVWpPZWNxV3ZvQ1lkNWYtOWVBMWZKcm1ocFVzVkxMQThRUW5WM0NJR0VpbGdFeGxGOWhHSHQ?oc=5","date":"2026-01-05","type":"pipeline","source":"BioSpace","summary":"AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug - BioSpace","headline":"AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQYklmVDFUWlh3dUdkdGlYSHRNQzlhck1IMGJZcVg5eFlxdUFaWjJhWXlEc2JBYno3NTZPcmVqY0RwOWh4eWNickZVbXZnVmswTkd5ZnRMMmo3VXN3RzAxQlhQVG91bWJIMms2eF9uRnlscnUzZUJDbmZYNWY0bFNQcWYzRnFtYVcxWHNmT1hzM0h5d0RabmNpazhINA?oc=5","date":"2026-01-02","type":"deal","source":"BioWorld News","summary":"New year sees Abbvie, Zelgen in $1.1B T-cell engager deal - BioWorld News","headline":"New year sees Abbvie, Zelgen in $1.1B T-cell engager deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBCQzNoMDM1NWxwRDdveWFvMFN5b090RWVFQkh6VUcxUlRldjgyY1RHX2FHME5OTUhkcXRCYURMMVJWbHhyT202b3hlb3RDaHZOZWNF?oc=5","date":"2025-12-31","type":"pipeline","source":"FirstWord Pharma","summary":"AbbVie doubles down on trispecifics with $1.2B bet on Zelgen's DLL3 asset - FirstWord Pharma","headline":"AbbVie doubles down on trispecifics with $1.2B bet on Zelgen's DLL3 asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQMkFqR3R5Mmw4WWdUTWVvN0xYM3R4YjVta1RrN0hZSnlNci02aHUtM2FVWEY3TXB2bDk2bEU5Sy1FOVZBZ0JScmtLdjZMc2lfMU9WNVIxblVBSkt2ZGFrNjVsdVNoU0RoS1o0MU9wNnh3RU84ZFJYWVFld1NmY3l2UmtRNnhJdFVpbnNneGhlQWwyNnpKa1Fyak1wVmNiTVgzUjNPdFhLZ0xIZF9FclItdmt0cG02UlVGM1pSdWEtZ2NZTUZWMEYySlJSbk82R090X0ZaZWw0dzluYVhkS3kzTXJTZTBySmJHNXFIcWF4QUNrQXY0UW9ROVhwaVVjTDFUUEhFMHAtaldMemhHTC1kOUVKRmZnRWFKaXZoRm1hOA?oc=5","date":"2025-08-14","type":"trial","source":"GlobeNewswire","summary":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma - GlobeNewswire","headline":"Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxQWHNuMmYyU0dYeFRna1RXMU02ck5fSklQZllyVFpBREZXNTRGOHJDejZGcGx4RzBFQzhXeDlpalAyOE8xWTlyTmZVUDAyZkhPV2xoNTZlRkRwOHBhUk14VnBOcEhQN3ZOaDdkb3lJZEdsaVRjWk9mS0tDRGU0VDRyQ0JYX0FlSHh5RjFaeWpab0hiNkwwZVk5NHhPNndOTGFPcWRpRjZJUllGVklqNEtZWnZGNVJidWJQbHA5SzYxRmJPT3JSdDZhZ0hKRjJFRmNUek9WUnU4R3NSOWt4bDhWTUI4RzB5WWYxXzRHa3RhbDU2a3UxY3RXYlBLbHNlLXU3bnNwazZEbS15MXFSdEVDaE5ZU0pfb0N2YXB0eWRTN0dQb3lzTTdaek5EMEFGaDVheng3ZFJkYw?oc=5","date":"2023-05-25","type":"trial","source":"PR Newswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in t","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNZHVkZFRxdnFCWHRsT1pkQWJieEItSXN2cHp2T0kzSEszMTdJa3JBVkFqMWFjZjJUR3dycWU1b24xM0htUmpRQXRvT01pQm5aaWtRM2tCMTN6RHVtaGpVdnVpc0pNUVJ0RmRGNHF3a2huUzBRSWRzT3ZHZ1oxdjlZVFkyUGZzNmlXQlN2OVJVV3IzTmg0UmFZaXZwMkJWSjcxa2x6WHlaaFpfNzRtWFdOQW9YNjZJbjlveEN1bk1jRHo0cTFkbTdpUkd6bzlLQ2xDMFUzcEpQcERqWmxxRDhYeFp5dEFLUXNELXlsQm82MXZrOTZvQzZtS19R?oc=5","date":"2021-10-06","type":"trial","source":"GlobeNewswire","summary":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight - GlobeNewswire","headline":"Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight","sentiment":"positive"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_1":3,"phase_3":5,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}